Connect with us

Press Release

3 Trends In Healthcare Guided By AI And The Companies Behind The Innovation

Published

6 months ago

on

–News Direct–

By Jeremy Golden, Benzinga

Artificial intelligence (AI) is on the cusp of transforming nearly every single industry. When it comes to healthcare, several trends have emerged.

As doctors and scientists continue to innovate, the market for AI in healthcare is expanding. The AI healthcare market appears poised for growth, with a market size of $22 billion in 2023 a number thats expected to accelerate at a CAGR of 36.4% from 2024-2030. The market for AI in healthcare is expected to reach $187.95 billion by 2030, demonstrating the transformative shift its brought to the healthcare industry.

AI-focused healthcare companies are driving this progress.

Here is how three healthcare companies are harnessing AIs capabilities, using technology to drive innovation, target treatments and increase access to healthcare.

Driving Innovation

The rapidly growing field of AI in healthcare is already coming to life at places like the Mayo Clinic, where several AI-powered medical and surgical improvements have validated new approaches to clinical care in cardiovascular medicine, neurology, oncology, radiology and other fields of medicine.

AI is replacing repetitive, manual processes such as patient data analysis that slow down healthcare professionals. Moving forward, this new technology will drive innovation, executives at Moderna (NASDAQ: MRNA) said after inking a partnership with OpenAI, the company behind ChatGPT, in April.

The move gave about 3,000 Moderna employees access to ChatGPT Enterprise, built on OpenAIs most advanced language model, GPT-4, the Wall Street Journal reports. Moderna anticipates the integration of AI could lead to the introduction of 15 new products by 2029, the Cambridge, Mass., company said.

Moderna CEO Stphane Bancel envisions employees using ChatGPT at least 20 times a day to reinvent all of Moderna's business processes, leading to greater overall efficiency. Heres one example.

When developing medicines, researchers study the biological and genetic variations that cause diseases to develop. Utilizing AI to dissect medical data sets like lab results can help scientists fill in the missing pieces. AI can assist them in figuring out the root cause of the disease, helping get much-needed treatments to patients faster.

AI can lift success rates to up to 50% while reducing a drugs time-to-market, a recent Moderna study by Harvard Universitys Digital Data Design Institute found.

AI is already transforming Moderna and enhancing its value-creation process. The companys position in AI-powered innovation is leading to more efficiency and scalability across the value chain due in large part to an AI-centric culture.

As of October 2023, nearly 65% of Moderna employees were active AI users. They have used the tool in multiple specific functions, from customized support to meaningful improvements in workflow efficiency and efficacy.

Moderna has plans to integrate AI into all aspects of the drug development life cycle. To that end, the company has launched the Moderna AI Academy to accelerate training on AI throughout the organization.

Targeted Treatments

In addition to advancing drug discovery, artificial intelligence is also helping treatments reach patients faster.

The past decade has seen an explosion in the amount of health data available to doctors. Organizing and analyzing this much data in a timely manner, however, can be a complex and time-consuming task for the human mind, no matter how capable or intelligent the person. Thats where AI comes in.

AI is enabling researchers to develop more targeted medicines, driving progress in the field of precision medicine. This trend was part of a presentation delivered by executives at Johnson & Johnson (NYSE: JNJ), who hosted a panel discussion about AIs role in transforming healthcare at this years South by Southwest conference. They touched on many topics, from AI applications in drug discovery to its ability to assist doctors during clinical trials.

When it comes to running clinical trials, one of the biggest challenges is quickly and efficiently recruiting and enrolling patients who meet the selection criteria.

By applying AI technology to the early stages of a clinical trial, Johnson & Johnson researchers can use large anonymized datasets to identify and locate clinical research sites with patients who could potentially benefit from the Johnson & Johnson medicines that are being studied.

From there, the clinical trial operations team can work to determine the likelihood of enrolling the newly identified sites into their trials.

Historically, many clinical trials have largely taken place at major academic medical centers, but we know that not all patients have access to these centers, said Nicole Turner, Senior Director of Global Development, Data Science & Digital Health and R&D at Janssen Pharmaceuticals. Our goal is to leverage the power of AI to bring trials to more patients, rather than waiting for patients to come to us.

According to The Wall Street Journal, Johnson & Johnson continues to make investments to the tune of hundreds of millions of dollars in AI and data science.

The company has hired about 6,000 data science and digital experts and opened a new research facility near San Francisco, and company executives say AI will power the companys drug discovery work and strengthen its pharmaceuticals business in the future.

Increasing Access

Across the country, there is a need for more accessible and systemic healthcare solutions. One company is responding by using AI to combat cardiovascular diseases globally while committing to health equity and access.

AI algorithms can effectively handle and analyze extensive medical data, including DNA biomarkers such as epigenetic and genetic information. As such, the shift to digital health and AI-driven diagnostics could also have widespread impacts on the cardiovascular detection, care and management industry, helping increase access to healthcare in a timely manner across the board especially helping underserved communities in the process.

Cardio Diagnostics (NASDAQ: CDIO), an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention and detection more precise, was formed to improve patient outcomes by developing and commercializing clinical tests that leverage AI-driven technology to combat cardiovascular disease.

The company is behind PrecisionCHDTM, the first integrated genetic-epigenetic test for the detection of coronary heart disease (CHD), the most common type of heart disease and the cause of most heart attacks. With the introduction of PrecisionCHD, clinicians are armed with a powerful, scalable and non-invasive alternative that comes in the form of a blood-based test that uses AI, along with personalized genetic and epigenetic information, to sensitively detect the presence of CHD and use the information for more personalized patient management.

Cardio Diagnostics has also developed Epi+Gen CHDTM, a powerful test that predicts the three-year risk for a CHD event, mainly a heart attack. Powered by AI-driven integrated genetics-epigenetics, the tool enables more effective decision-making and earlier interventions.

Traditional diagnostic methods for CHD, often inaccessible due to the need for specialized infrastructure, can be invasive and sometimes require exposure to ionizing radiation. Additionally, some of the tests are not sensitive to all forms of CHD and can be very costly, resulting in millions of Americans left without adequate and potentially lifesaving cardiac care. Thanks to AI, PrecisionCHD has armed clinicians with a powerful, scalable and non-invasive alternative that comes in the form of a blood-based test.

For rural communities where access to specialized medical facilities is limited, the implications of this advancement are particularly relevant. With only a simple blood draw needed to complete a test, PrecisionCHD offers patients in underserved areas access to state-of-the-art cardiac assessments.

PrecisionCHD can be administered in primary care or telemedicine settings, significantly reducing the need for patients to travel to distant specialized clinics. This level of availability, marking a step forward toward mitigating healthcare disparities, would not be possible without AI.

Featured photo by CDC on Unsplash.

Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine (Core Technology) for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease. For more information, please visit www.cardiodiagnosticsinc.com.

Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases will, "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intend," goal, or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Companys ability to compete, regulatory matters, protection of technology, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Current Report on Form 10-K for the period ended December 31, 2022 and Form 10-Q for the period ended March 31, 2023, under the heading Risk Factors in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release.

This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.

Contact Details

Gene Mannheimer – Investor Relations

+1 855-226-9991

investors@cardiodiagnosticsinc.com

Company Website

https://cardiodiagnosticsinc.com/

View source version on newsdirect.com: https://newsdirect.com/news/3-trends-in-healthcare-guided-by-ai-and-the-companies-behind-the-innovation-489286769

Cardio Diagnostics Holdings, Inc

comtex tracking

COMTEX_451714604/2655/2024-05-01T08:30:21

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Related Topics:
Continue Reading

Press Release

New World Asset Management Ltd NWAM and AlgoDynamix reach a comprehensive strategic cooperation Leading the new era of intelligent risk management

Published

1 hour ago

on

October 24, 2024

By

In the ever-changing global financial market, investors have an increasing demand for accurate market insights and intelligent risk management. Market volatility, emergencies and global economic uncertainty have brought unprecedented challenges to investors. However, in the face of these changes, New World Asset Management (NWAM) and AlgoDynamix have joined forces to provide global investors with forward-looking market risk management solutions to help them remain invincible in market fluctuations.

United States, 24th Oct 2024 – In the ever-changing global financial market, investors have an increasing demand for accurate market insights and intelligent risk management. Market volatility, emergencies and global economic uncertainty have brought unprecedented challenges to investors. However, in the face of these changes, New World Asset Management (NWAM) and AlgoDynamix have joined forces to provide global investors with forward-looking market risk management solutions to help them remain invincible in market fluctuations.

As a leading global risk analysis company, AlgoDynamix relies on its unique AI and big data analysis technology to focus on predicting market volatility and risk management. The market volatility prediction tools provided by AlgoDynamix have been widely used in many financial institutions around the world, helping investors to make plans before market fluctuations. Its innovative risk prediction system allows investors to adjust their strategies in time when the market fluctuates violently to avoid potential losses.  In November 2023 , NWAM and AlgoDynamix officially launched strategic cooperation negotiations. The two parties quickly determined the cooperation framework and decided to integrate AlgoDynamix’s market risk prediction model with NWAM’s AI quantitative trading platform. This integration will not only greatly enhance NWAM’s market analysis capabilities, but also provide its users with intelligent market volatility early warning functions.

In early 2024, the two parties successfully completed the integration of market data and risk prediction tools, and officially released the AI-driven market volatility early warning system on the NWAM platform. The system can monitor market dynamics in real time, capture potential risk signals, and provide users with instant risk warnings. With this technology, NWAM users can quickly respond to market changes and adjust investment strategies to achieve more stable wealth growth.  One of the important results of this cooperation is the launch of an intelligent risk management system. Through this system, NWAM users can not only obtain accurate market volatility forecasts, but also use intelligent tools for personalized risk management. Whether it is large institutional investors or individual investors, the NWAM platform will help them make smarter decisions amid market uncertainty.  Commenting on the partnership, NWAM CEO said: “We have always believed that the future of financial markets belongs to those companies that can fully leverage smart technology. AlgoDynamix’s technology fits seamlessly with our AI quantitative trading platform, providing our users with powerful risk management tools. This partnership marks a key step forward in our journey towards smart investment management.”

The founder of AlgoDynamix is also looking forward to the cooperation: “NWAM’s leading technology in digital asset management and AI trading perfectly complements our expertise in predicting market volatility. We firmly believe that through this cooperation, global investors will be able to better protect their assets during market turmoil and achieve steady wealth appreciation.”  This cooperation not only promotes the advancement of intelligent risk management technology, but also opens a new chapter in safer and more reliable wealth management for global investors. Through its cooperation with AlgoDynamix, NWAM will significantly enhance its capabilities in market analysis and risk management. The AI-driven market fluctuation early warning system and intelligent risk management functions not only improve the platform’s market response capabilities, but also bring more security to investors. In an increasingly complex global market, improving risk management capabilities is undoubtedly an important cornerstone for investors to make steady profits.

Media Contact

Organization: New World Asset Management Ltd

Contact Person: Don Adam Perera

Website: https://newworldeco.com

Email: Send Email

Country: United States

Release Id: 24102418963

The post New World Asset Management Ltd NWAM and AlgoDynamix reach a comprehensive strategic cooperation Leading the new era of intelligent risk management appeared on King Newswire. It is provided by a third-party content provider. King Newswire makes no warranties or representations in connection with it.

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Eagle Crest Asset Management and Its AI Ambitions A Global Expansion

Published

1 hour ago

on

October 24, 2024

By

United States, 24th Oct 2024 – Since its founding in 2019, Eagle Crest Asset Management has been steadfast in its commitment to providing long-term value to clients through professional investment management and meticulous risk control strategies. With a client-first approach, the firm has built a strong reputation for its innovative solutions and personalized investment strategies, which are designed to meet the unique financial goals of each client. As the company evolves, it is turning its focus towards a new frontier: artificial intelligence (AI).

Eagle Crest’s Growing Focus on AI

In today’s rapidly changing financial landscape, technology and AI are becoming critical components in shaping the future of asset management. Recognizing this trend, Eagle Crest has identified the AI industry as a key area for future growth and investment. The firm plans to intensify its research and development efforts in AI, aiming to discover and invest in promising AI startups and enterprises that show potential for long-term success.

By leveraging cutting-edge AI technologies, Eagle Crest intends to enhance its investment strategies, enabling more sophisticated portfolio management and improving predictive analytics for better market forecasting. The firm is particularly focused on identifying companies at the forefront of AI innovation, those developing groundbreaking applications across industries such as healthcare, robotics, autonomous systems, and big data analytics.

Strategic Global Expansion

To support its ambitious AI focus, Eagle Crest Asset Management is expanding its global footprint. Over the next few years, the company plans to establish offices in dozens of regions worldwide. This global expansion will provide the firm with a more diverse and extensive network, allowing it to tap into local AI ecosystems and identify promising investment opportunities in key markets.

By setting up operations in major innovation hubs, including North America, Europe, Asia, and the Middle East, Eagle Crest aims to build strong partnerships with local AI companies, researchers, and innovators. These offices will also serve as research centers, helping the company stay ahead of emerging trends and technological advancements in AI. This global presence will not only enhance Eagle Crest’s access to high-potential AI startups but will also allow the firm to support them through funding, mentorship, and strategic partnerships.

A Vision for the Future

Founder Ridel Bosco Castillo has always been a visionary leader, driving Eagle Crest’s growth and innovation. With this new focus on AI, Castillo sees tremendous opportunities to shape the future of asset management by integrating advanced technologies into the investment process. He believes that by fostering AI innovation, Eagle Crest can generate superior returns for its clients while also contributing to the advancement of AI industries worldwide.

As Eagle Crest Asset Management continues to evolve, its AI-driven strategies and global expansion will position the firm as a leader in both the financial and technology sectors. The company’s commitment to finding and investing in the best AI enterprises, combined with its robust network of global offices, will enable it to stay at the forefront of the industry, offering clients access to cutting-edge investment opportunities and solutions.

In the coming years, Eagle Crest aims to become a key player in the AI space, bridging the gap between finance and technology while delivering unparalleled value to its clients. This strategic move marks the beginning of a new chapter for the firm, one where AI and global innovation will drive its future success.

Media Contact

Organization: Eagle Crest Asset Management

Contact Person: Ridel Bosco Castillo

Website: https://ecamai.com/

Email: Send Email

Country: United States

Release Id: 24102418964

Disclaimer: Investments in artificial intelligence (AI) and related technologies are subject to significant risks, including technological challenges, market volatility, and unpredictable regulatory environments. Clients and prospective investors should perform their own due diligence and consider their financial goals, risk tolerance, and consult with financial advisors before making investment decisions. All information provided is for informational purposes only and should not be construed as financial advice.

The post Eagle Crest Asset Management and Its AI Ambitions A Global Expansion appeared on King Newswire. It is provided by a third-party content provider. King Newswire makes no warranties or representations in connection with it.

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

EMEET Recognized with Multiple Prestigious Awards for EMEET AirFlow and EMEET Meeting Capsule Pro Room Kit

Published

2 hours ago

on

October 24, 2024

By

China, 24th Oct 2024 – EMEET, a leader in AI-driven audio and video communication solutions, recently received prestigious recognition for its innovative products. The EMEET AirFlow Open-Ear Headphones have been honored with Japan’s G-Mark Design Award and earned Zoom certification. Additionally, the EMEET Meeting Capsule Pro Room Kit has won the prestigious IDEA Award.

Award Highlights

The G-Mark Design Award, also known as the Good Design Award, is a significant accolade in Japan, recognizing outstanding design and innovation. Being Zoom certified underscores EMEET’s commitment to providing superior audio and video experiences that meet industry standards.

The IDEA (International Design Excellence Awards) is one of the premier awards in the field of industrial design. Winning this award stands as a testament to EMEET’s relentless pursuit of groundbreaking and user-friendly products.

Award-Winning Product Overview

EMEET AirFlow

EMEET AirFlow Open-Ear Headphones combine cutting-edge technology with elegant design, providing users with an exceptional auditory experience that ensures situational awareness and comfort. With the detachable microphone design, the EMEET AirFlow is not only a ideal choice for daily entertainment, but also an office essential for professionals.

The recognition by G-Mark and Zoom certification highlights its excellence in both design and functionality.

EMEET Meeting Capsule Pro Room Kit

The EMEET Meeting Capsule Pro Room Kit combines a camera, speaker, and microphone into one sleek device, eliminating the need for multiple pieces of equipment and simplifying the setup process. This all-in-one design ensures a seamless meeting experience in one compact package.

Winning the IDEA Award showcases EMEET’s dedication to creating products that blend advanced technology with user-centric design.

About EMEET

EMEET values the contributions of every individual in meetings and knows that everyone should be heard and seen. Established in August 2016, with the mission of “better communication, better world”, EMEET endeavored to create an intelligent mobile collaboration space. Today, EMEET is a prominent global company, specializing in R&D, production, and sales of AI-driven intelligent audio and video communication products.

The Zoom-Certified AirFlow will be available in December, 2024.

Media Contact

Organization: EMEET TECHNOLOGY CO., LTD

Contact Person: Amy Lyu

Website: https://emeet.com/

Email: Send Email

Country: China

Release Id: 24102418947

The post EMEET Recognized with Multiple Prestigious Awards for EMEET AirFlow and EMEET Meeting Capsule Pro Room Kit appeared on King Newswire. It is provided by a third-party content provider. King Newswire makes no warranties or representations in connection with it.

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST

Like Us
Follow Us
Subscribe Us
Follow Us